Open AccessNatalizumab in Crohn’s Disease
Author(s) -
Atsushi Sakuraba,
Kian Keyashian,
Chase Correia,
John Melek,
Russell D. Cohen,
Stephen B. Hanauer,
David T. Rubin
Publication year - 2013
Publication title -
inflammatory bowel diseases
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1097/mib.0b013e31827eea78
Subject(s) - natalizumab , medicine , crohn's disease , disease , tumor necrosis factor alpha , inflammatory bowel disease , immunology , clinical trial , crohn disease , gastroenterology
Natalizumab is an efficacious agent for the induction and maintenance of remission in patients with Crohn's disease (CD) who have failed anti-tumor necrosis factor (TNF) agents. We aimed to assess the efficacy and safety of natalizumab outside of clinical trial at a US tertiary center.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom